TrialSignal
Clinical trial intelligence report
An Open-label Clinical Study on the Efficacy and Safety of CD7-specific CAR-T Cell Injection in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT06720324
Status
RECRUITING
Phase
Phase 1/2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Executive brief
Investment-Ready Snapshot
The clinical trial focuses on CD7-specific CAR-T cell therapy for patients with relapsed/refractory hematologic malignancies, a significant unmet need in oncology. The potential market for CAR-T therapies is expanding, particularly in hematologic cancers, with increasing competition from established players and emerging biotech firms. Successful outcomes could position the sponsor, Union Hospital, and its collaborator, Hebei Taihe Chunyu Biotechnology Co., Ltd, favorably within this growing market. Diligence should consider the regulatory landscape, potential partnerships, and the evolving competitive environment in CAR-T therapies.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06720324
Indication
Hematologic Malignancy
Modality
cell therapy
Target
CD7-positive hematologic tumors
Intervention
Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.